TULSA, Okla., Dec. 11 /PRNewswire/ -- Plymouth Pharmaceuticals(R), Inc. announced today that it has launched a new oral prescription medication for the treatment of acne and rosacea.
Dermatologist, Dr. Steven A. Smith, MD, FACP, based in Tulsa, Okla. was searching for a better way to treat his acne patients and formulated Acunol(TM) as a result. "Acunol(TM) is a safe biochemical compound with fewer side effects than most prescription acne treatments currently available, and it contains no antibiotics," Dr. Smith said, a fellow of the American College of Physicians.
"Acunol(TM) is an antibiotic-free, prescription medication for the treatment of mild to moderate acne and rosacea; the tablets can be swallowed, chewed, or dissolved by mouth for easy usage by any person," Miles Smith, the company's Vice President, said. Side effects are few and Acunol(TM) has only minimal contraindications (see prescribing insert). Acunol's price is competitive with other prescriptions acne treatments, as well.
McKesson and Cardinal Health, two of the largest drug wholesale distributors have decided to stock Acunol(TM); pharmacies routinely use one of these distributors to fill a prescription.
A retrospective clinical case study in treating acne and rosacea with Acunol(TM) either in combination therapy or alone has been completed with positive results; 8 out of 10 patients stated that their acne/rosacea had improved at least moderately (data on file).
Acunol(TM) is an effective, inexpensive, safe, and easy to use alternative to less safe, expensive, and largely ineffective prescription acne treatments currently sold by most pharmaceutical companies.
Plymouth Pharmaceuticals(R), Inc.
